GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shenzhen Weiguang Biological Products Co Ltd (SZSE:002880) » Definitions » Debt-to-Revenue

Shenzhen Weiguang Biological Products Co (SZSE:002880) Debt-to-Revenue : 0.75 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Shenzhen Weiguang Biological Products Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Shenzhen Weiguang Biological Products Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥145 Mil. Shenzhen Weiguang Biological Products Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥530 Mil. Shenzhen Weiguang Biological Products Co's annualized Revenue for the quarter that ended in Mar. 2025 was ¥900 Mil. Shenzhen Weiguang Biological Products Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 was 0.75.


Shenzhen Weiguang Biological Products Co Debt-to-Revenue Historical Data

The historical data trend for Shenzhen Weiguang Biological Products Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Weiguang Biological Products Co Debt-to-Revenue Chart

Shenzhen Weiguang Biological Products Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.05 0.82 0.50 0.57

Shenzhen Weiguang Biological Products Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.57 0.53 0.49 0.75

Competitive Comparison of Shenzhen Weiguang Biological Products Co's Debt-to-Revenue

For the Biotechnology subindustry, Shenzhen Weiguang Biological Products Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Weiguang Biological Products Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shenzhen Weiguang Biological Products Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shenzhen Weiguang Biological Products Co's Debt-to-Revenue falls into.


;
;

Shenzhen Weiguang Biological Products Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Shenzhen Weiguang Biological Products Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(116.451 + 569.416) / 1203.192
=0.57

Shenzhen Weiguang Biological Products Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(144.565 + 530.112) / 900.008
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2025) Revenue data.


Shenzhen Weiguang Biological Products Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shenzhen Weiguang Biological Products Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Weiguang Biological Products Co Business Description

Traded in Other Exchanges
N/A
Address
Guangming Street, No. 3402, Guangqiao Avenue, Guangming New District, Guangdong Province, Guangming, CHN, 518107
Shenzhen Weiguang Biological Products Co Ltd is the pharmaceutical company. It is mainly engaged in the research and development, production and sales of blood products. The company's products portfolio includes human albumin, intravenous immunoglobulin (pH4), lyophilized human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, rabies immunoglobulin, tetanus Human immunoglobulin, histamine human immunoglobulin, human fibrinogen, a total of 21 varieties of 21 specifications.
Executives
Guo Cai Ping Executives

Shenzhen Weiguang Biological Products Co Headlines

No Headlines